PHILLIPSBURG, N.J., Oct. 27 /PRNewswire/ -- Celldex Therapeutics, Inc. today announced that Robert F. Burns, Ph.D., the Company’s President and CEO, will present a corporate overview at the C.E. Unterberg, Towbin Life Sciences Conference. The presentation will take place at 1:00 p.m. EST on Monday, October 30, 2006, at the Palace Hotel in New York City. For details on this event, please visit http://www.unterberg.com.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a biotechnology company focused on developing fully human antibody-based products that target and stimulate the body’s immune system for the treatment of cancer, infectious and autoimmune diseases. The Company’s lead product, CDX-110, is scheduled to have entered a definitive Phase 2/3 clinical trial for the treatment of newly diagnosed glioblastoma by early 2007. Celldex has three product candidates already in or about to enter clinical development targeting multiple cancers as well as Hepatitis B. Four additional product candidates are in preclinical development for cancer and autoimmune disease. Celldex’s proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells - key cells within the immune system. Celldex was formed in 2004 as a spin-out from Medarex, Inc. . The Company is headquartered in Phillipsburg, New Jersey and also has R&D operations in Cambridge, UK. For more information, please visit the website: http://www.celldextherapeutics.com.
Celldex Therapeutics, Inc.
CONTACT: Anthony Marucci, Vice President\Chief Financial Officer ofCelldex Therapeutics Inc., +1-908-454-7120,amarucci@celldextherapeutics.com; or John Quirk of The Ruth Group,+1-646-536-7029, jquirk@theruthgroup.com; or Dan Budwick of BMCCommunications, +1-212-477-9007 x14, daniel@bmccommunications.com
